ClinicalTrials.gg
CompletedNCT05591079Updated Nov 16, 2026Results posted

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

A Phase 2 interventional study of CS0159 (Linafexor) in Nonalcoholic Steatohepatitis (NASH), sponsored by Cascade Pharmaceuticals, Inc. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Cascade Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
166th of 460
99 · median 56
Started
2023
with 36 others
Phase 2
192 of 547
15 open now
Registered
461st of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 166th largest by enrollment of the 460 interventional ones that give a count, is one of 37 that started in 2023, is one of 192 in phase 2, and was the 461st registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)

Read the detailed description

This will be a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PKs, and efficacy of CS0159 in the treatment of patients with NASH over 12 weeks.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who meet the diagnosis of NASH.
  2. Evidence of metabolic syndrome, except for those patients with -proven NASH.
  3. (BMI) >25 kg/m2, NOTE: for Asian-Americans BMI >23 kg/m2.
  4. Stable use of other antidiabetic, weight loss, or lipid-modifying medications for at least 12 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Use of other drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer.
  2. Previous exposure to farnesoid X receptor (FXR) agonists 3 months prior to the first dosing.
  3. Current or within 6 months of screening use of drugs associated with steatosis, including but not limited to eg, methotrexate, amiodarone, high-dose estrogen, tamoxifen, long term systemic , anabolic steroids, valproic acid.
  4. international normalized ratio >1.3, unless due to therapeutic anticoagulation.
  5. Total > (ULN; except for patients with Gilbert's syndrome with a normal direct bilirubin value and normal reticulocyte count).

    count \<140 000/mm³, \<1500 cells/mm3, or total

  6. white blood cells \<3000 cells/mm3.
  7. and aspartate aminotransferase (AST) >5 × ULN, or alkaline phosphatase (ALP) >1.5 × ULN.
  8. Weight changes >10% in 6 months prior to screening, or weight changes >5% from the screening MRI-PDFF to randomization or from the time of the diagnostic liver to randomization, whichever is longer.
  9. Poorly controlled hypertension (systolic >160 mm Hg, or diastolic blood pressure >100 mm Hg - mean of 3 measurements).
  10. Uncontrolled diabetes mellitus ( >10.0% during screening).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    1.4mg CS0159

    One tablet daily for 12 weeks

    Drug: CS0159 (Linafexor)

  • Experimental
    2mg CS0159

    One tablet daily for 12 weeks

    Drug: CS0159 (Linafexor)

  • Placebo comparator
    PLACEBO

    One tablet daily for 12 weeks

    Drug: CS0159 (Linafexor)

Interventions

06

What researchers measure

Primary outcomes

  1. MRI-PDFF

    To assess the percentage changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12

    Time frame: Week 12

  2. Adverse Events

    To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks

    Time frame: Week 12

Secondary outcomes

  1. Cmax

    maximum concentration (Cmax)

    Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.

  2. Tmax

    time to maximum plasma concentration (tmax)

    Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.

  3. t1/2

    half-life (t1/2)

    Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.

  4. AR(AUC)

    accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to day42

    Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.

  5. Pharmacodynamics (PD)-Fibroblast Growth Factor 19

    Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 from baseline to day42

    Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.

  6. Pharmacodynamics (PD)-C4

    Plasma concentrations and PD parameters of the biomarkers of FXR target engagement 7-alpha-Hydroxy-4-cholesten-3-one(C4) from baseline to day42

    Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.

07

Results

Posted Nov 16, 2026

Participant flow

This multicenter study was conducted at 17 sites in the United States of America between 10 February 2023 and 04 May 2023

Participant flow — Overall Study
Milestone1.4mg CS01592mg CS0159PLACEBO
Started394020
Completed343719
Not completed531

Outcome measures

PrimaryMRI-PDFF

To assess the percentage changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12

Time frame:
Week 12
Reported as:
Mean · percentage change
MRI-PDFF
percentage change1.4mg CS01592mg CS0159PLACEBO
MRI-PDFF-4.08 ± 47.042-14.10 ± 27.227-4.34 ± 24.563
PrimaryAdverse Events

To evaluate the safety and tolerability of CS0159 in patients with NASH treated over 12 weeks

Time frame:
Week 12
Reported as:
Count of participants · Participants
Adverse Events
Participants1.4mg CS01592mg CS0159PLACEBO
Adverse Events222211
SecondaryCmax

maximum concentration (Cmax)

Time frame:
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Reported as:
Geometric mean · ng/mL
Cmax
ng/mL1.4mg CS0159(day1)2mg CS0159(day1)1.4mg CS0159(day42)2mg CS0159(day42)
Cmax10.3 ± 95.715.6 ± 56.310.1 ± 60.616.4 ± 45.9
SecondaryTmax

time to maximum plasma concentration (tmax)

Time frame:
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Reported as:
Median · h
Tmax
h1.4mg CS0159(day1)2mg CS0159(day1)1.4mg CS0159(day42)2mg CS0159(day42)
Tmax0.550 (0.467 to 3.00)0.950 (0.500 to 1.33)0.550 (0.483 to 1.02)0.550 (0.500 to 1.02)
Secondaryt1/2

half-life (t1/2)

Time frame:
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Reported as:
Geometric mean · h
t1/2
h1.4mg CS0159(day1)2mg CS0159(day1)1.4mg CS0159(day42)2mg CS0159(day42)
t1/21.17 ± 37.51.15 ± 24.91.36 ± 27.81.17 ± 27.7
SecondaryAR(AUC)

accumulation ratio of area under the concentration-time curve (AUC) in plasma from baseline to day42

Time frame:
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Reported as:
Geometric mean · Unitless
AR(AUC)
Unitless1.4mg CS01592mg CS0159
AR(AUC)1.02 ± 29.20.944 ± 24.4
SecondaryPharmacodynamics (PD)-Fibroblast Growth Factor 19

Plasma concentrations and PD parameters of the biomarkers of FXR target engagement fibroblast growth factor 19 from baseline to day42

Time frame:
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Reported as:
Mean · pg/mL
Pharmacodynamics (PD)-Fibroblast Growth Factor 19
pg/mL1.4mg CS0159(day1)2mg CS0159(day1)Placebo(day1)1.4mg CS0159(day42)2mg CS0159(day42)Placebo(day42)
predose138.38 ± 121.702128.09 ± 148.453140.59 ± 102.064113.07 ± 130.626134.27 ± 154.692139.38 ± 93.679
0.5h92.79 ± 89.338110.25 ± 144.398164.64 ± 144.56777.26 ± 56.45485.91 ± 89.842110.21 ± 88.913
1h118.56 ± 86.303107.55 ± 103.224151.99 ± 99.154130.84 ± 156.455313.98 ± 1067.777126.65 ± 85.892
1.5h111.35 ± 92.887177.04 ± 141.541155.91 ± 113.146106.49 ± 119.510136.41 ± 103.774117.81 ± 86.580
2h302.80 ± 310.163383.05 ± 274.093150.88 ± 105.402279.22 ± 250.961503.97 ± 412.934134.60 ± 107.081
3h857.76 ± 604.031874.42 ± 412.733148.72 ± 100.988760.87 ± 439.3891093.75 ± 571.917206.28 ± 141.046
5h899.63 ± 497.6481198.97 ± 490.641196.83 ± 141.3281038.65 ± 775.0371092.79 ± 546.569261.29 ± 145.023
SecondaryPharmacodynamics (PD)-C4

Plasma concentrations and PD parameters of the biomarkers of FXR target engagement 7-alpha-Hydroxy-4-cholesten-3-one(C4) from baseline to day42

Time frame:
Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
Reported as:
Mean · ng/mL
Pharmacodynamics (PD)-C4
ng/mL1.4mg CS0159(day1)2mg CS0159(day1)1.4mg CS0159(day42)2mg CS0159(day42)Placebo(day1)Placebo(day42)
predose43.594 ± 51.490942.536 ± 41.476734.863 ± 33.597234.703 ± 27.771930.506 ± 22.327648.996 ± 48.8304
0.5 h57.836 ± 68.098532.835 ± 23.253437.306 ± 41.175630.279 ± 16.671827.614 ± 20.721244.609 ± 41.4394
1h51.170 ± 63.233938.959 ± 37.465043.553 ± 48.798835.549 ± 27.234030.622 ± 21.331344.692 ± 40.7742
1.5h69.451 ± 84.941331.223 ± 20.411439.218 ± 45.465833.472 ± 19.961126.792 ± 17.010045.776 ± 40.0685
2h66.830 ± 82.206327.834 ± 17.953839.639 ± 44.851331.833 ± 18.972523.023 ± 12.627251.759 ± 45.0546
3h54.829 ± 61.235322.233 ± 13.892946.215 ± 51.551125.724 ± 14.186116.446 ± 8.996655.370 ± 42.5373
5h25.147 ± 29.249913.454 ± 8.229345.214 ± 48.881114.445 ± 8.52538.548 ± 5.691047.482 ± 33.3965

Adverse events

Collected over from enrollment until end of follow-up, up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.4mg CS01590/39 (0%)0/39 (0%)22/39 (56.4%)
2mg CS01590/40 (0%)2/40 (5%)20/40 (50%)
PLACEBO0/20 (0%)1/20 (5%)10/20 (50%)
Most frequent serious events
Most frequent serious events
Event1.4mg CS01592mg CS0159PLACEBO
OsteoarthritisMusculoskeletal and connective tissue disorders0/390/401/20
Femur fractureInjury, poisoning and procedural complications0/391/400/20
AppendicitisInfections and infestations0/391/400/20
Most frequent other events
Showing 10 of 67
Most frequent other events
Event1.4mg CS01592mg CS0159PLACEBO
PruritusSkin and subcutaneous tissue disorders7/399/405/20
HyperglycaemiaMetabolism and nutrition disorders3/395/400/20
Abdominal pain upperGastrointestinal disorders4/390/400/20
ContusionInjury, poisoning and procedural complications4/391/402/20
Skin lacerationInjury, poisoning and procedural complications0/390/402/20
Upper respiratory tract infectionInfections and infestations0/393/400/20
FlatulenceGastrointestinal disorders2/392/400/20
ConstipationGastrointestinal disorders2/390/401/20
Pain in extremityMusculoskeletal and connective tissue disorders2/392/400/20
HeadacheNervous system disorders2/391/400/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)1.4mg CS01592mg CS0159PLACEBOTotal
Mean55.7 ± 9.6853.7 ± 11.9657.7 ± 9.1855.3 ± 10.58
Sex: Female, Male
Sex: Female, Male(Participants)1.4mg CS01592mg CS0159PLACEBOTotal
Female1720845
Male22201254
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.4mg CS01592mg CS0159PLACEBOTotal
American Indian or Alaska Native0011
Asian0213
Native Hawaiian or Other Pacific Islander0000
Black or African American1618
White37311785
More than one race0000
Unknown or Not Reported1102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.4mg CS01592mg CS0159PLACEBOTotal
Hispanic or Latino23231258
Not Hispanic or Latino1517840
Unknown or Not Reported1001
MRI-PDFF
MRI-PDFF(percentage of liver fat content)1.4mg CS01592mg CS0159PLACEBOTotal
Mean17.70 ± 6.12115.71 ± 6.94415.95 ± 5.83316.54 ± 6.419
08

Study locations

17 sites
  • National Research Institute - Gardena
    Gardena, California 90247-3586, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255-2959, United States
  • Velocity Clinical Research - Panorama City
    Panorama City, California 91402-3022, United States
  • Velocity Clinical Research - Santa Ana
    Santa Ana, California 92704, United States
  • Ocala GI Research
    Lady Lake, Florida 32159, United States
  • Florida Research Institute
    Lakewood, Florida 34211-4930, United States
  • San Marcus Research Clinic, Inc - Miami
    Miami, Florida 33014-5602, United States
  • Floridian Clinical Research, LLC - Miami Lakes
    Miami Lakes, Florida 33016-1518, United States
  • Gastroenterology Associates of Ocala
    Ocala, Florida 34471, United States
  • Oracle Clinical Research
    College Park, Georgia 30349, United States
  • Metropolitan Gastroenterology Associates - Westbank Office and Endoscopy
    Marrero, Louisiana 70072, United States
  • Raja M. Din MD, PLLC - Gastroenterology & Hepatology
    Greenbelt, Maryland 20770-6702, United States
  • Lucas Research
    Morehead City, North Carolina 28557, United States
  • Texas Liver Institute (TLI) - Austin
    Austin, Texas 78757-7571, United States
  • Pioneer Research Solutions Inc - Houston - Stancliff Rd
    Houston, Texas 77099-4307, United States
  • The Texas Liver Institute, Inc.
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas, LLC
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2023, 8 months.

Results were first posted in Nov 2026, 3 years after primary completion.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's 8 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2022
First posted
Oct 24, 2022
StartActual
Feb 10, 2023
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Primary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedAdverse eventsEventsTime frame: Week 12
  • DescriptionMRI-PDFF: how it is measured was reworded
Nov 16, 2026
Documents
Secondary outcomes
2 edited, 2 time frame changed, 2 added, 1 removed, 2 description edited
What changed in the outcomes
  • EditedtmaxTmaxTime frame: week 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
  • EditedPharmacodynamics AR(PDAUC)Time frame: week 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
  • AddedPharmacodynamics (PD)-Fibroblast Growth Factor 19Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
  • AddedPharmacodynamics (PD)-C4Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
  • RemovedAUCTime frame: week 6, week 12
  • Time frameCmaxweek 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
  • Time framet1/2week 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
  • DescriptionCmax: how it is measured was reworded
  • Descriptiont1/2: how it is measured was reworded
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedAdverse eventsEventsTime frame: Week 12
    • DescriptionMRI-PDFF: how it is measured was reworded
    Secondary outcomes 2 edited, 2 time frame changed, 2 added, 1 removed, 2 description edited
    What changed in the outcomes
    • EditedtmaxTmaxTime frame: week 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
    • EditedPharmacodynamics AR(PDAUC)Time frame: week 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
    • AddedPharmacodynamics (PD)-Fibroblast Growth Factor 19Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
    • AddedPharmacodynamics (PD)-C4Time frame: Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
    • RemovedAUCTime frame: week 6, week 12
    • Time frameCmaxweek 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
    • Time framet1/2week 6, week 12 → Day 1 and Day 42: pre-dose (0 hour) and 0.5, 1, 1.5, 2, 3, and 5 hours post-dose.
    • DescriptionCmax: how it is measured was reworded
    • Descriptiont1/2: how it is measured was reworded
    + 3 other changes: index terms, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05591079
Lead sponsor
Cascade Pharmaceuticals, Inc
Collaborators
Laboratory Corporation of America
Responsible party
Sponsor
First posted
Oct 24, 2022
Start date
Feb 10, 2023
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Rong Deng
study director · Cascade Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linafexor

Start the discussion